A non-toxic analogue of a coeliac-activating gliadin peptide

A basis for immunomodulation?

F. Biagi, H. J. Ellis, N. D J Parnell, R. G. Shidrawi, P. D. Thomas, N. O'Reilly, G. R. Corazza, P. J. Ciclitira

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.

Original languageEnglish
Pages (from-to)945-950
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume13
Issue number7
DOIs
Publication statusPublished - 1999

Fingerprint

Gliadin
Immunomodulation
Celiac Disease
Abdomen
Poisons
Peptides
Galectin 3
Organ Culture Techniques
Alanine
peptide A
Biopsy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Biagi, F., Ellis, H. J., Parnell, N. D. J., Shidrawi, R. G., Thomas, P. D., O'Reilly, N., ... Ciclitira, P. J. (1999). A non-toxic analogue of a coeliac-activating gliadin peptide: A basis for immunomodulation? Alimentary Pharmacology and Therapeutics, 13(7), 945-950. https://doi.org/10.1046/j.1365-2036.1999.00512.x

A non-toxic analogue of a coeliac-activating gliadin peptide : A basis for immunomodulation? / Biagi, F.; Ellis, H. J.; Parnell, N. D J; Shidrawi, R. G.; Thomas, P. D.; O'Reilly, N.; Corazza, G. R.; Ciclitira, P. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 13, No. 7, 1999, p. 945-950.

Research output: Contribution to journalArticle

Biagi, F. ; Ellis, H. J. ; Parnell, N. D J ; Shidrawi, R. G. ; Thomas, P. D. ; O'Reilly, N. ; Corazza, G. R. ; Ciclitira, P. J. / A non-toxic analogue of a coeliac-activating gliadin peptide : A basis for immunomodulation?. In: Alimentary Pharmacology and Therapeutics. 1999 ; Vol. 13, No. 7. pp. 945-950.
@article{af020cb176e54f2c8bc5afe64c6558eb,
title = "A non-toxic analogue of a coeliac-activating gliadin peptide: A basis for immunomodulation?",
abstract = "Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.",
author = "F. Biagi and Ellis, {H. J.} and Parnell, {N. D J} and Shidrawi, {R. G.} and Thomas, {P. D.} and N. O'Reilly and Corazza, {G. R.} and Ciclitira, {P. J.}",
year = "1999",
doi = "10.1046/j.1365-2036.1999.00512.x",
language = "English",
volume = "13",
pages = "945--950",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - A non-toxic analogue of a coeliac-activating gliadin peptide

T2 - A basis for immunomodulation?

AU - Biagi, F.

AU - Ellis, H. J.

AU - Parnell, N. D J

AU - Shidrawi, R. G.

AU - Thomas, P. D.

AU - O'Reilly, N.

AU - Corazza, G. R.

AU - Ciclitira, P. J.

PY - 1999

Y1 - 1999

N2 - Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.

AB - Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.

UR - http://www.scopus.com/inward/record.url?scp=0033001147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033001147&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1999.00512.x

DO - 10.1046/j.1365-2036.1999.00512.x

M3 - Article

VL - 13

SP - 945

EP - 950

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 7

ER -